Navigation Links
AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference
Date:11/13/2012

CASTLE ROCK, Colo., Nov. 13, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that it will present at the 9th Annual Lazard Capital Markets Healthcare Conference, held November 13-14, 2012, at the Pierre Hotel in New York City.  

Steve Lundy, President and CEO of AspenBio, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.Event:2012 Lazard Capital Markets Healthcare ConferenceDate: Wednesday, November 14, 2012 Time: 2:30 pm (Eastern Time) Location:Regency B room; Pierre Hotel, New York, NYAbout AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.aspenbiopharma.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from AppyScore, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com 
jrando@tiberend.com

 


'/>"/>
SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AspenBio to Present at 2012 Aegis Healthcare Conference
2. AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
5. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
6. Regulus to Present at the Lazard Capital Markets Healthcare Conference
7. Heptares to Present at BIO-Europe 2012
8. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
9. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10. Organovo To Present At Lazard Healthcare Conference
11. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... ... Biova, LLC., the leader in water soluble egg membrane ingredients, announced today ... bring a wealth of scientific experience in the food, beverage, nutrition and dietary supplement ... of four major global companies in the last 4 decades. He has a ...
(Date:6/22/2017)... , ... June 21, 2017 , ... ... and hiring top executive talent in the life sciences industry, today announces a ... company. The partnership takes full advantage of Beaker’s expertise in executive recruitment ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy ... and perspectives by leading experts on the unique regulatory challenges of stem cell ...
(Date:6/20/2017)... Hill, CT (PRWEB) , ... June 20, 2017 ... ... support, today announced that the CTNext board of directors has formed a Higher ... by a working group composed of institution presidents and other high-ranking representatives from ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
Breaking Biology News(10 mins):